Prophylactic uses of integrin CD18-βA peptide in a murine polymicrobial peritonitis model

World Journal of Gastroenterology

Volumn 16, Issue 21, 2010, Pages 2648-2656

  Wong, Kwong Fai ^a,b   Wo, Jana ^b   Ho, David ^b   Poon, Ronnie T ^b   Casasnovas, José M ^c   Luk, John M ^a,b  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^b QUEEN MARY HOSPITAL   (Hong Kong)

^c CSIC   (Spain)

Author keywords

Bacterial endotoxin; Biotherapeutic peptide; Inflammation; Integrin CD18

Indexed keywords

CD3 ANTIGEN; CD45 ANTIGEN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTEGRIN CD18 BETA A PEPTIDE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; MESSENGER RNA; SYNTHETIC PEPTIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL PERITONITIS; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG POTENCY; LETHALITY; MALE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; OPTIMAL DRUG DOSE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SEPSIS;

EID: 77953495377     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v16.i21.2648     Document Type: Article

References (33)

1. Pfeiffer R. Untersuchungen über das Choleragift. Z Hyg 1892; 11: 393-411
2. Luk JM, Lind SM, Tsang RS, Lindberg AA. Epitope mapping of four monoclonal antibodies recognizing the hexose core domain of Salmonella lipopolysaccharide. J Biol Chem 1991; 266: 23215-23225
3. Rittirsch D, Flierl MA, Ward PA. Harmful molecular mechanisms in sepsis. Nat Rev Immunol 2008; 8: 776-787
4. Russell JA. Management of sepsis. N Engl J Med 2006; 355: 1699-1713
5. Németh K, Leelahavanichkul A, Yuen PS, Mayer B, Par-melee A, Doi K, Robey PG, Leelahavanichkul K, Koller BH, Brown JM, Hu X, Jelinek I, Star RA, Mezey E. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-depen-dent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med 2009; 15: 42-49
6. Wang H, Liao H, Ochani M, Justiniani M, Lin X, Yang L, Al-Abed Y, Wang H, Metz C, Miller EJ, Tracey KJ, Ulloa L. Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat Med 2004; 10: 1216-1221
7. Yan JJ, Jung JS, Lee JE, Lee J, Huh SO, Kim HS, Jung KC, Cho JY, Nam JS, Suh HW, Kim YH, Song DK. Therapeutic effects of lysophosphatidylcholine in experimental sepsis. Nat Med 2004; 10: 161-167
8. Wong KF, Luk JM, Cheng RH, Klickstein LB, Fan ST. Characterization of two novel LPS-binding sites in leukocyte integrin betaA domain. FASEB J 2007; 21: 3231-3239
9. Calandra T, Echtenacher B, Roy DL, Pugin J, Metz CN, Hül-tner L, Heumann D, Männel D, Bucala R, Glauser MP. Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med 2000; 6: 164-170
10. Sun S, Poon RT, Lee NP, Yeung C, Chan KL, Ng IO, Day PJ, Luk JM. Proteomics of hepatocellular carcinoma: serum vi-mentin as a surrogate marker for small tumors (
11. Lee NP, Tsang S, Cheng RH, Luk JM. Increased solubility of integrin betaA domain using maltose-binding protein as a fusion tag. Protein Pept Lett 2006; 13: 431-435
12. Villa P, Shaklee CL, Meazza C, Agnello D, Ghezzi P, Sen-aldi G. Granulocyte colony-stimulating factor and antibiotics in the prophylaxis of a murine model of polymicrobial peritonitis and sepsis. J Infect Dis 1998; 178: 471-477
13. Ho DW, Fan ST, To J, Woo YH, Zhang Z, Lau C, Wong J. Selective plasma fltration for treatment of fulminant hepatic failure induced by D-galactosamine in a pig model. Gut 2002; 50: 869-876
14. Luk JM, Kumar A, Tsang R, Staunton D. Biotinylated lipo-polysaccharide binds to endotoxin receptor in endothelial and monocytic cells. Anal Biochem 1995; 232: 217-224
15. Luk JM, Tung PH, Wong KF, Chan KL, Law S, Wong J. Laparoscopic surgery induced interleukin-6 levels in serum and gut mucosa: implications of peritoneum integrity and gas factors. Surg Endosc 2009; 23: 370-376
16. Yu XM, Lo CY, Lam AK, Leung P, Luk JM. Serum vascular endothelial growth factor C correlates with lymph node metastases and high-risk tumor profles in papillary thyroid carcinoma. Ann Surg 2008; 247: 483-489
17. Luk JM, Wang PP, Lee CK, Wang JH, Fan ST. Hepatic potential of bone marrow stromal cells: development of in vitro co-culture and intra-portal transplantation models. J Immunol Methods 2005; 305: 39-47
18. Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, Silke J, Fan ST, Luk JM, Wigler M, Hannon GJ, Mu D, Lu-cito R, Powers S, Lowe SW. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 2006; 125: 1253-1267
19. Lee NP, Leung KW, Wo JY, Tam PC, Yeung WS, Luk JM. Blockage of testicular connexins induced apoptosis in rat seminiferous epithelium. Apoptosis 2006; 11: 1215-1229
20. Steinberg D, Khoo JC, Glass CK, Palinski W, Almazan F. A new approach to determining the rates of recruitment of circulating leukocytes into tissues: application to the measurement of leukocyte recruitment into atherosclerotic lesions. Proc Natl Acad Sci USA 1997; 94: 4040-4044
21. Liu LX, Lee NP, Chan VW, Xue W, Zender L, Zhang C, Mao M, Dai H, Wang XL, Xu MZ, Lee TK, Ng IO, Chen Y, Kung HF, Lowe SW, Poon RT, Wang JH, Luk JM. Targeting cadherin-17 inactivates Wnt signaling and inhibits tumor growth in liver carcinoma. Hepatology 2009; 50: 1453-1463
22. Luk JM, Lai W, Tam P, Koo MW. Suppression of cytokine production and cell adhesion molecule expression in human monocytic cell line THP-1 by Tripterygium wilfordii poly-saccharide moiety. Life Sci 2000; 67: 155-163
23. Zender L, Xue W, Zuber J, Semighini CP, Krasnitz A, Ma B, Zender P, Kubicka S, Luk JM, Schirmacher P, McCombie WR, Wigler M, Hicks J, Hannon GJ, Powers S, Lowe SW. An oncogenomics-based in vivo RNAi screen identifes tumor suppressors in liver cancer. Cell 2008; 135: 852-864
24. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994; 76: 301-314
25. Wong KF, Luk JM. Endotoxin-neutralizing peptides as gram-negative sepsis therapeutics. Protein Pept Lett 2009; 16: 539-542
26. Riedemann NC, Guo RF, Ward PA. Novel strategies for the treatment of sepsis. Nat Med 2003; 9: 517-524
27. Reinhart K, Karzai W. Anti-tumor necrosis factor therapy in sepsis: update on clinical trials and lessons learned. Crit Care Med 2001; 29: S121-S125
28. Fisher CJ Jr, Dhainaut JF, Opal SM, Pribble JP, Balk RA, Slotman GJ, Iberti TJ, Rackow EC, Shapiro MJ, Greenman RL. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 1994; 271: 1836-1843
29. Bone RC. The pathogenesis of sepsis. Ann Intern Med 1991; 115: 457-469
30. Menger MD, Vollmar B. Adhesion molecules as determinants of disease: from molecular biology to surgical research. Br J Surg 1996; 83: 588-601
31. Chan KL, Wong KF, Luk JM. Role of LPS/CD14/TLR4-mediated infammation in necrotizing enterocolitis: patho-genesis and therapeutic implications. World J Gastroenterol 2009; 15: 4745-4752
32. Warren HS, Amato SF, Fitting C, Black KM, Loiselle PM, Pas-ternack MS, Cavaillon JM. Assessment of ability of murine and human anti-lipid A monoclonal antibodies to bind and neutralize lipopolysaccharide. J Exp Med 1993; 177: 89-97
33. Carlsson M, Lipcsey M, Larsson A, Tano E, Rubertsson S, Eriksson M, Sjölin J. Inflammatory and circulatory effects of the reduction of endotoxin concentration in established porcine endotoxemic shock--a model of endotoxin elimination. Crit Care Med 2009; 37: 1031-1034